Uzawa Katsuhiro, Kasamatsu Atsushi, Shimizu Toshihiro, Saito Yasuhiro, Baba Takao, Sakuma Kentaro, Fushimi Kazuaki, Sakamoto Yosuke, Ogawara Katsunori, Shiiba Masashi, Tanzawa Hideki
1] Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba, Japan [2] Department of Dentistry-Oral and Maxillofacial Surgery, Chiba University Hospital, Chiba, Japan.
Department of Dentistry-Oral and Maxillofacial Surgery, Chiba University Hospital, Chiba, Japan.
Sci Rep. 2014 Jun 25;4:5433. doi: 10.1038/srep05433.
No definitive therapy exists to treat human metastatic tumors. We reported previously that down-regulation of Lin-7C is essential for metastasis of human squamous cell carcinomas (hSCCs). In this study, we investigated the chemical restoration of Lin-7C expression and demonstrated its effectiveness for suppressing the metastatic potential in human cancer cells. Ingenuity Pathway Analysis (IPA) identified candidate chemical agents, i.e., apomorphine, caffeine, risperidone, quetiapine, and mirtazapine. Among them, mirtazapine, an antagonist of HTR2C, an upstream molecule of Lin-7C, caused substantial up-regulation of the Lin-7C/β-catenin pathway in a metastatic hSCC cell line and human melanoma-derived cell line in vitro, and up-regulation did not contribute to cellular proliferation. Moreover, the antimetastatic effect of mirtazapine in these metastatic cell lines in vivo also was evident in multiple organs of immunodeficient mice with no marked side effects. The current data offer novel information for further study of antimetastatic activity in association with enhanced Lin-7C/β-catenin pathway activation with mirtazapine.
目前尚无明确的疗法可用于治疗人类转移性肿瘤。我们之前报道过,Lin-7C的下调对人类鳞状细胞癌(hSCC)的转移至关重要。在本研究中,我们研究了Lin-7C表达的化学恢复,并证明了其对抑制人类癌细胞转移潜能的有效性。通路分析软件(IPA)确定了候选化学试剂,即阿扑吗啡、咖啡因、利培酮、喹硫平和米氮平。其中,米氮平是Lin-7C的上游分子HTR2C的拮抗剂,在体外可使转移性hSCC细胞系和人黑色素瘤来源的细胞系中的Lin-7C/β-连环蛋白通路显著上调,且上调与细胞增殖无关。此外,米氮平在这些转移性细胞系中的体内抗转移作用在免疫缺陷小鼠的多个器官中也很明显,且无明显副作用。目前的数据为进一步研究米氮平增强Lin-7C/β-连环蛋白通路激活与抗转移活性之间的关系提供了新的信息。